97950 Faculty of Medicine, University of British Columbia, Kelowna, Canada.
3158 Faculty of Pharmacy, University of Alberta, Canada.
J Cutan Med Surg. 2020 May/Jun;24(3):292-296. doi: 10.1177/1203475420909794. Epub 2020 Mar 5.
Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.
克立硼罗，一种局部磷酸二酯酶-4 抑制剂，于 2016 年被批准用于治疗成人和 2 岁以上儿童的轻至中度特应性皮炎。自那时以来，已经发表了几项关于克立硼罗在治疗其他炎症性皮肤病方面的标签外使用的病例报告和小型随机对照试验。本文回顾了目前有限的关于克立硼罗治疗银屑病、脂溢性皮炎、白癜风和炎症性线状疣状表皮痣的标签外使用的证据。还根据其作用机制推测了克立硼罗的其他潜在治疗用途。需要进一步的研究来阐明克立硼罗的全部治疗潜力；然而，它是当前炎症性皮肤病的非甾体类局部治疗的一个受欢迎的补充。
